Forter Enables Merchants to Offer Competitive Returns Policies without Worry
Forter, the leader in e-commerce fraud prevention, today announced the release of Forter Returns Abuse Protection. The new solution enables merchants to identify and block abusive returns practices, allowing merchants to confidently offer competitive policies their shoppers expect.
38% of online shoppers indicate that return policies have a major impact on their decision to purchase from any retailer. Nearly 1 in 4 have abandoned a shopping cart due to poor returns options, and 31% of consumers would not shop again at a retailer following a difficult returns experience. Merchants offer liberal returns policies to satisfy rising consumer expectations in an increasingly competitive market.
With 10% of all items sold in the United States returned, merchandise returns are forecast to cost American retailers $550 Billion in 2020. Fraudulent returns comprise a significant percentage of this sum, costing retailers $24 Billion annually, according to research published by Appriss.
“Well-established retailers are curtailing or altogether eliminating their flexible returns policies because of the cost of abuse. It’s very unfortunate that a few people can spoil a terrific consumer experience for everyone,” said Michael Reitblat, CEO and Co-Founder of Forter. “With Forter retailers can now proactively and fairly enforce their online returns policies, and still deliver a best-in-class experience their loyal customers expect.”
Returns abuse impacts merchants in a variety of ways:
- Lost Revenue: Abusive returns remove inventory from stock that could have been sold to legitimate customers. Additionally, only 50% of returned items can be resold at full price due to product wear and tear.
- Operational Overhead & Costs: Costs associated with processing returns, restocking inventory and shipping cut into overall profit.
- Degraded Customer Experience: Returns abuse can make it financially unfeasible for a merchant to support a customer-friendly returns program, which results in a poor customer experience and also reduces the lifetime value of new and existing customers.
Consumers use different means to take advantage of returns policies:
- “Wardrobing” or “Free Renting”: Abusers purchase an item, use it once, and return the item for a refund. Most commonly associated with apparel, this practice extends to other types of items as well.
- High Return Rates: Consumers return a high percentage of orders back to the merchant, using different cards and addresses to hide the practice.
- Returns Fraud: Abusers return a different, often less valuable, item while collecting the value of the original item.
- Appeasements: Consumers initiate multiple or false complaints about the quality of an item for a discount or refund.
- Risk-free inventory: Resellers buy inventory at promotional prices to sell at full price, then return unsold inventory.
“Returns abuse is a major challenge for retailers. It impacts profitability and threatens their ability to provide a competitive customer experience,” said Vikrant Gandhi, Industry Director at Frost & Sullivan. “Forter’s Returns Abuse Protection enables merchants to accurately identify abusers, both online and offline, so they can offer consumer-friendly policies. With the collective intelligence of its Global Merchant Network, Forter analyzes consumer behavior across all customer touch points to identify and stop abuse.”
Forter’s Returns Abuse Solution provides merchants with:
- Approve/decline decisions at every transaction, enabling merchants to block returns abusers from placing more orders that will likely result in additional returns.
- Approve/decline decisions at every returns initiation, at the point of the returns request (e.g. online, call center agent).
- Flagged suspicious accounts, enabling merchants to enforce policies at the account-level; for example, making repeat abusers ineligible for free returns shipping or only allowing in-store returns.
- Full dashboard, Track returns KPIs with an in-depth view of return data from a single, easy-to-use dashboard.
Forter’s Returns Abuse Protection is part of its broader Policy Abuse Protection offering, protecting merchants against item-not-received abuse, promo/coupon abuse, reseller abuse and reshipper abuse.
Read more at forter.com
Forter is the leader in e-commerce fraud prevention, processing over $150 billion in online commerce transactions and protecting over 620 million consumers globally from credit card fraud, account takeover, identity theft, and more. The company’s identity-based fraud prevention solution detects fraudulent activity in real-time, throughout all online consumer experiences.
Forter’s integrated fraud prevention platform is powered by its rapidly growing Global Merchant Network, underpinned by predictive fraud research and modeling, and the ability for customers to tailor the platform for their specific needs. As a result, Forter is trusted by Fortune 500 companies to deliver exceptional accuracy, a smoother user experience, and elevated sales at a much lower cost. Forter was recently named the Leader in e-Commerce Fraud Prevention by Frost & Sullivan.
Forter is backed by $100M of capital from top-tier VCs including Sequoia, NEA, and Salesforce.
fama PR for Forter
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esri Offers Students Free Access to Software for Continued Education Through Coronavirus Closures30.3.2020 16:29:00 EEST | Press release
Esri, the global leader in location intelligence, today announced that it will provide free access to its ArcGIS platform and learning resources through the Learn.ArcGIS.com website to support college and university students who no longer have access to campus computer labs during the COVID-19 outbreak. Students will receive access to ArcGIS Online and over 20 apps including ArcGIS Pro, along with a library of lessons to continue their learning and complete courses. Access is available globally to students ages 18 and over. Learn ArcGIS promotes learning by doing through guided lessons based on real-world problems in industries such as urban planning and disaster response, and new lessons on public health have just been added. Learn ArcGIS lessons cover both beginner and advanced topics and are available in seven languages. “We believe education creates opportunities for people of all ages, while building communities and advancing our knowledge for a better world,” said Jack Dangermond
Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan30.3.2020 15:00:00 EEST | Press release
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma and related lymphomas. In January 2017, Daiichi Sankyo received exclusive development, manufacturing and commercialization rights for axicabtagene ciloleucel in Japan from California-based Kite, a Gilead Company. The Japan NDA submission is based on previous pivotal trial data conducted globally by Kite for axicabtagene ciloleucel in addition to results from a phase 2 bridging study conducted by Daiichi Sankyo in Japan. Both trials included patients with four aggressive types of relapsed/refractory B-cell lymphomas including diffuse large B cell lymphoma (DLBCL); primary mediastinal B-cell lymphoma (PMBCL); transformed follicular lymphoma (TF
Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform30.3.2020 15:00:00 EEST | Press release
Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease areas, today announced that it is initiating an additional research and development project targeting the coronavirus group and has completed initial screening under the Smart-ACT™ platform, a repurposed and new drug discovery platform, to select, out of more than 2,600 approved small drug molecules, at least 3 potential candidates for further preclinical investigation against the new coronavirus disease, COVID-19. Aptorum Group is collaborating with Toronto based Covar Pharmaceuticals and has also entered into agreement with the University of Hong Kong’s Microbiology Department to conduct further preclinical investigation of the selected candidates prior to seeking approval from regulatory agencies to initiate clinical trials on suitable candidates. In particular, Aptoru
HCL Technologies COVID-19 Status Update30.3.2020 11:40:00 EEST | Press release
HCL Technologies Ltd (HCL) has been monitoring the Covid-19 outbreak since late January and had invoked its Business Continuity Plan and Risk Management Framework quite early to minimize the impact on its employees and clients. The situation arising out of this outbreak and its rapid spread across the world is unprecedented and is extremely dynamic. The economic impact is visible with varying degrees of intensity across multiple countries where we operate. HCL has had a well-defined and structured pandemic policy in place which is resilient, pragmatic and accords paramount importance to employee safety & health and client commitments. We are actively engaged with our clients and have executed the client-specific and HCL internal operations-centric Business Continuity Plan that ensures continuity in delivering to our client and employee commitments. HCL is constantly reviewing the situation at hand with utmost priority and fully complying with all government advisories and recommendatio
GSMA Report Highlights That Mobile Money Accounts Now Exceed One Billion Worldwide30.3.2020 11:00:00 EEST | Press release
The GSMA today unveiled the annual ‘State of the Industry Report on Mobile Money’, offering a view of the mobile money landscape and highlighting the impact that greater financial inclusion has on lives, economies and innovation, especially in emerging markets. This year’s report looks at what one billion registered accounts means for the mobile money industry, mobile money users and the future of the mobile money ecosystem. It provides a comprehensive picture of adoption and usage around the globe. Significantly, the report highlights that 2019 marked a major milestone for the mobile money industry, with over one billion registered accounts and close to two billion dollars in daily transactions. For the first time, digital transactions represented the majority, 57 per cent, of mobile money interactions. The industry is witnessing increasing user trust and relevance. With 290 live services in 95 countries and 372 million active accounts, mobile money is entering the mainstream and beco
Benefits of bempedoic acid in hypercholesterolaemia further demonstrated by data presented at the American College of Cardiology’s 69th Annual Scientific Sessions Together with World Congress of Cardiology (ACC.20/WCC)30.3.2020 10:00:00 EEST | Press release
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced results from two pooled analyses from four Phase 3 clinical trials for bempedoic acid and separate results from a Phase 2 study of the bempedoic acid / ezetimibe fixed dose combination (FDC). The data were presented at the American College of Cardiology’s 69th Scientific Sessions Together with World Congress of Cardiology virtual experience (ACC.20/WCC). The 12-week Phase 2 bempedoic acid / ezetimibe FDC study (also known as Study 058) enrolled adult patients with type 2 diabetes mellitus (T2DM) at high risk of cardiovascular disease.6 The bempedoic acid / ezetimibe FDC reduced LDL-C by 40% compared to placebo with no increase in glycated haemoglobin (HbA1c), indicating that glycaemic control was not adversely affected.6 The bempedoic acid / ezetimibe FDC was well tolerated in Study 058, and the incidence of adverse events rates were generally comparable to placebo.6 The first pooled analysis of four Phase 3 clini
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom